Literature DB >> 495485

Nifedipine therapy for refractory coronary arterial spasm.

F A Heupler, W L Proudfit.   

Abstract

Nifedipine was evaluated in the management of eight patients with intractable coronary arterial spasm. All had Prinzmetal's variant angina, normal or mildly abnormal coronary arteriograms, and a positive ergonovine maleate provocative test. Anginal attacks occurred at least three times a week in all patients during isosorbide dinitrate therapy. All patients had a decrease in frequency of ischemic attacks with nifedipine. Seven patients underwent repeat Holter monitor evaluation, which confirmed the absence of ischemic changes while they were taking nifedipine. When nifedipine dosage was decreased.or therapy discontinued in six patients, all experienced a recurrence of anginal attacks. Two patients had minor side effects, which required a decrease in the dose of nifedipine. Nifedipine was well tolerated, and no major complications occurred with its use. Nifedipine appears to be effective in the management of patients with symptomatic coronary arterial spasm and normal or mildly abnormal coronary arteriograms. Our data justify further investigation of nifedipine for treatment of such patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 495485     DOI: 10.1016/0002-9149(79)90200-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring.

Authors:  H Kambara; I H Mohiuddin; N Tamaki; T Fudo; M Hayashi; R Nohara; J Konishi; C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Vasodilatory effects of nisoldipine on coronary arteries--correlation with plasma levels.

Authors:  S Jost; W Rafflenbeul; B Mogwitz; D Gulba; H Hecker; P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  Adverse reactions to calcium antagonists.

Authors:  J G Lewis
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

4.  Calcium channel blockers.

Authors:  P C Deedwania
Journal:  West J Med       Date:  1982-07

Review 5.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

6.  Differential effects of the calcium antagonist, verapamil, on lumen sizes of terminal arterioles and muscular venules in the rat mesenteric, pial and skeletal muscle microvasculatures.

Authors:  B M Altura; B T Altura; A Gebrewold
Journal:  Br J Pharmacol       Date:  1980-11       Impact factor: 8.739

7.  Intravenous nifedipine prevents ergonovine-induced myocardial ischemia in patients with stable effort angina.

Authors:  C Brunelli; P Spallarossa; G Ghigliotti; M Caudullo; M Iannetti; S Caponnetto
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

8.  Nifedipine impairs neutrophil respiratory burst by a mechanism other than calcium channel blockade.

Authors:  K Nalini; K I Andrabi; N K Ganguly; P L Wahi
Journal:  Mol Cell Biochem       Date:  1990-03-05       Impact factor: 3.396

9.  Rebound of vasospastic angina after cessation of long-term treatment with nifedipine.

Authors:  J Lette; R M Gagnon; J G Lemire; M Morissette
Journal:  Can Med Assoc J       Date:  1984-05-01       Impact factor: 8.262

10.  Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina.

Authors:  T E Meyer; C Adnams; P Commerford
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.